ERCC1、BRCA1、RRM1表达在晚期非小细胞肺癌个体化治疗中的前瞻性研究  

Prospective study of ERCC1,BRCA1,and RRM1 expression on the individualized treatment of advanced non-small cell lung cancer

作　　者：丁剑午 唐罗勇[1,2] 艾素芬 张峰皓 黄龙 胡蓉环 熊强[1,2] 

机构地区：[1]江西省肿瘤基础及转化研究重点实验室,江西南昌330000 [2]南昌大学第二附属医院肿瘤科,江西南昌330000

出　　处：《中国当代医药》2017年第32期56-58,共3页China Modern Medicine

摘　　要：目的探讨切除修复交叉互补基因1(ERCC1)、乳腺癌易感基因1(BRCA1)、核糖核苷酸还原酶M1亚基(RRM1)表达在晚期非小细胞肺癌(NSCLC)个体化治疗中的应用价值。方法选择2015年6月~2016年8月在我院就诊的晚期NSCLC患者50例作为研究对象,采取奇偶数分组模式进行分组,每组25例,其中实验组对ERCC1、BRCA1、RRM1水平进行检测,依据检测结果对化疗方案进行选择,常规组直接给予吉西他滨联合顺铂治疗。比较两组的治疗效果。结果实验组的化疗总有效率为72.00%,明显高于常规组的56.00%,差异有统计学意义(P<0.05);两组患者的生活质量与化疗前比较均明显改善,但两组治疗后的PS评分差异无统计学意义(P>0.05);实验组发生12例血液系统反应,7例消化道反应,3例其他;常规组发生13例血液系统反应,7例消化道反应,3例其他,两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论对ERCC1、BRCA1、RRM1水平进行检测,并依据检测水平指导晚期NSCLC患者的治疗,便于提高临床效果。Objective To investigate the application value of excision repair cross-complementing gene 1 （ERCC1）, breast cancer susceptibility gene 1 （BRCA1）,and ribonucleotide reductase M1 subunit （RRM1） expression in the indi- vidualized treatment of advanced non-small cell lung cancer （NSCLC）.Methods From June 2015 to August 2016,50 patients with advanced NSCLC visited our hospital were recruited as research subjects.Using an odd/even number grouping model,they were grouped and there were 25 cases in each group.In the experimental group,the level of ER- CC1,BRCAI,and RRMI were tested,and the corresponding chemotherapy regimen was selected based on the outcomes. In the conventional group,Gemcitabine combined with Cisplatin was provided.The therapeutic effect was compared be- tween the two groups.Results The total effective rate of chemotherapy in the experimental group was 72.00%,which was obviously higher than that of the conventional group,and there was a statistical difference （P〈0.05）.The quality of life in both groups was improved compared with that before chemotherapy,but there was no significant difference of PS score between the two groups （P〉0.05）.In the experimental group,there were blood system reaction in 12 cases,digestive tract reaction in 7 cases,and other in 3 ones.In the conventional group,there were blood system reaction in 13 cases,digestive tract reaction in 7 cases,and other in 3 ones.There was no statistical difference of the incidence of adverse reaction between the two groups （P〉0.05）.Conclusion Test for the level of ERCC1,BRCAI,and RRM1 and guidance of clinical treatment in NSCLC patients based on the outcomes are beneficial to improve the clinical therapeutic effect.

关 键 词：晚期非小细胞肺癌 个体化治疗 ERCC1 BRCA1 RRM1 

分 类 号：R734.2[医药卫生—肿瘤]